About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Production of growth and jobs figures:

  • The growth potential of the sectors identified in this release (life sciences, aerospace and clean energy) was produced by WPI Economics for the ABPI in April 2019. These sectors were selected on the basis that they are the most highly productive of the industries Government is working with in its sector deals (see Figure 4 and information about sector deals, below).
  • Growth and jobs projections were calculated by mapping existing data on the current direct contribution to the UK economy of the three sectors, then subjecting this to conservative assumptions about future growth potential, which indicated that £44bn per annum would be added to the economy by 2025 from a baseline of £30bn in 2017 (£14bn net additional direct GVA). A link outlining the methodology and data sources can be seen by following this link: https://wpi-strategy.com/technical-note-projecting-growth-jobs-innovation-economy/
  • The projected impacts are summarised below in Figure 1:

Figure 1: GVA and Employment impacts to 2025

Direct Gross Value Added (GVA) impact (2017) - £30bn

Consisting of:

  • Life Sciences: £14bn
  • Aerospace: £10bn
  • Clean Energy: £6bn

Direct Gross Value Added (GVA) impact (2025) - £44bn

Consisting of:

  • Life Sciences: £22.5bn
  • Aerospace: £14.6bn
  • Clean Energy: £7bn

Employment (2017) – 350,000

Consisting of:

  • Life Sciences: 190,000
  • Aerospace: 110,000
  • Clean Energy: 50,000

Employment (2025) – 406,000

Consisting of:

  • Life Sciences: 221,400
  • Aerospace: 27,200
  • Clean Energy: 57,400

Figure 2: productivity (GVA per employee) in industries with sector deals

  • Life Sciences - £72,000
  • Aerospace - £91,000
  • Clean Energy £122,000
  • Rail - £69,000
  • Construction - £48,000
  • Automotive - £40,000
  • Creative Industries - £50,000

Note: comparable figures for artificial intelligence and nuclear sectors, which also have sector deals, are not available

Sector deals are partnerships between government and industry on sector-specific issues can create significant opportunities to boost productivity, employment, innovation and skills. They have to date focused on innovative sectors that use science and technology to create new value or to transform production methods. Information about sector deals can be found at this link from HM Government: https://www.gov.uk/government/publications/industrial-strategy-sector-deals/introduction-to-sector-deals

 

Media enquiries


+44 (0) 20 7747 7147​​